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Abstract
A multifunctional, ubiquitous molecule, adenosine acts at cell-surface G protein-coupled receptors, as well as
numerous enzymes, including protein kinases and adenylyl cyclase. Extracellular adenosine is thought to be
produced either by export or by metabolism, predominantly through ecto-5-nucleotidase activity (also producing
inorganic phosphate). It is inactivated either by extracellular metabolism via adenosine deaminase (also
producing ammonia) or, following uptake by nucleoside transporters, via adenosine deaminase or adenosine
kinase (requiring ATP as co-substrate). Intracellular adenosine may be produced by cytosolic 5-nucleotidases
or through S-adenosylhomocysteine hydrolase (also producing L-homocysteine).
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This is a citation summary for Adenosine turnover in the Guide to Pharmacology database (GtoPdb). It exists
purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation
analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here
under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
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